immuno-oncology

Researchers working in orphan indications, immuno-oncology, respiratory diseases, diabetes, and other key areas invited to submit a brief Statement of Interest

The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI’s industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and IRICoR/Merck.

The program’s goal is to secure funding for researchers within MI’s membership through these collaborative, strategic R&D partnership programs.

The program is open to any researcher affiliated with MI’s 16 member institutions working on technologies in:

• Orphan indications
• Immuno-oncology
• Respiratory system diseases (e.g., Chronic obstructive pulmonary disease (COPD), asthma, lung cancer, etc.)
• Diabetes
• Neuroscience
• Orthopaedics
• General surgery

Successfully run in November 2013 and March 2014, the MI-IAP allows researchers to easily determine whether an industry partner is interested in co-developing their technologies. The application process is deliberately brief at the outset.